Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.

<h4>Objective</h4>Research biopsies are an essential component of cancer clinical trials for studying drug efficacy and identifying biomarkers. Site-level clinical investigators, however, do not have access to results on the adequacy of research biopsies for histological or molecular ass...

Full description

Bibliographic Details
Main Authors: Kyoungmin Lee, So Jung Lee, Shinkyo Yoon, Baek-Yeol Ryoo, Sang-We Kim, Sang Hyun Choi, Sang Min Lee, Eun Jin Chae, Yangsoon Park, Se-Jin Jang, Soo-Yeon Park, Young-Kwang Yoon, Seong Ho Park, Tae Won Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0221065
id doaj-68a6ddbe30e946449329986d65d496e6
record_format Article
spelling doaj-68a6ddbe30e946449329986d65d496e62021-03-04T10:26:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01148e022106510.1371/journal.pone.0221065Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.Kyoungmin LeeSo Jung LeeShinkyo YoonBaek-Yeol RyooSang-We KimSang Hyun ChoiSang Min LeeEun Jin ChaeYangsoon ParkSe-Jin JangSoo-Yeon ParkYoung-Kwang YoonSeong Ho ParkTae Won Kim<h4>Objective</h4>Research biopsies are an essential component of cancer clinical trials for studying drug efficacy and identifying biomarkers. Site-level clinical investigators, however, do not have access to results on the adequacy of research biopsies for histological or molecular assays, because samples are sent to central labs and the test results are seldom reported back to site-level investigators unless requested. We evaluated the feasibility, safety, and adequacy of research biopsies performed at an academic medical center.<h4>Materials and methods</h4>We retrospectively reviewed the data on 122 research biopsy sessions conducted in 99 patients via percutaneous core needle biopsy for 39 clinical trials from January 2017 to February 2018 at a single institute. We asked the sponsors of each clinical trial for the adequacy of the biopsy samples for histological or molecular assays.<h4>Results</h4>The biopsy success rate was 93.4% (113/122), with nine samples categorized as inadequate for obtaining pathologic diagnosis. Post-biopsy complications occurred in 9.8% (12/122) of biopsies, all of which were mild and completely recovered by the day after the biopsy. The sponsors of clinical trials provided feedbacks on the adequacy of 76 biopsy samples, and noted that a total of 8 biopsy samples from 7 patients were inadequate for analysis, resulting in an adequacy rate of 89.5% (68/76): the reasons for inadequacy were insufficient tumor content for immunohistochemistry (n = 3) and low RNA yield for sequencing (n = 5).<h4>Conclusion</h4>Research biopsies performed at an experienced, multidisciplinary center had acceptable safety for patients as well as practicality in terms of obtaining adequate tissue samples for molecular studies.https://doi.org/10.1371/journal.pone.0221065
collection DOAJ
language English
format Article
sources DOAJ
author Kyoungmin Lee
So Jung Lee
Shinkyo Yoon
Baek-Yeol Ryoo
Sang-We Kim
Sang Hyun Choi
Sang Min Lee
Eun Jin Chae
Yangsoon Park
Se-Jin Jang
Soo-Yeon Park
Young-Kwang Yoon
Seong Ho Park
Tae Won Kim
spellingShingle Kyoungmin Lee
So Jung Lee
Shinkyo Yoon
Baek-Yeol Ryoo
Sang-We Kim
Sang Hyun Choi
Sang Min Lee
Eun Jin Chae
Yangsoon Park
Se-Jin Jang
Soo-Yeon Park
Young-Kwang Yoon
Seong Ho Park
Tae Won Kim
Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
PLoS ONE
author_facet Kyoungmin Lee
So Jung Lee
Shinkyo Yoon
Baek-Yeol Ryoo
Sang-We Kim
Sang Hyun Choi
Sang Min Lee
Eun Jin Chae
Yangsoon Park
Se-Jin Jang
Soo-Yeon Park
Young-Kwang Yoon
Seong Ho Park
Tae Won Kim
author_sort Kyoungmin Lee
title Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
title_short Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
title_full Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
title_fullStr Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
title_full_unstemmed Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
title_sort feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Objective</h4>Research biopsies are an essential component of cancer clinical trials for studying drug efficacy and identifying biomarkers. Site-level clinical investigators, however, do not have access to results on the adequacy of research biopsies for histological or molecular assays, because samples are sent to central labs and the test results are seldom reported back to site-level investigators unless requested. We evaluated the feasibility, safety, and adequacy of research biopsies performed at an academic medical center.<h4>Materials and methods</h4>We retrospectively reviewed the data on 122 research biopsy sessions conducted in 99 patients via percutaneous core needle biopsy for 39 clinical trials from January 2017 to February 2018 at a single institute. We asked the sponsors of each clinical trial for the adequacy of the biopsy samples for histological or molecular assays.<h4>Results</h4>The biopsy success rate was 93.4% (113/122), with nine samples categorized as inadequate for obtaining pathologic diagnosis. Post-biopsy complications occurred in 9.8% (12/122) of biopsies, all of which were mild and completely recovered by the day after the biopsy. The sponsors of clinical trials provided feedbacks on the adequacy of 76 biopsy samples, and noted that a total of 8 biopsy samples from 7 patients were inadequate for analysis, resulting in an adequacy rate of 89.5% (68/76): the reasons for inadequacy were insufficient tumor content for immunohistochemistry (n = 3) and low RNA yield for sequencing (n = 5).<h4>Conclusion</h4>Research biopsies performed at an experienced, multidisciplinary center had acceptable safety for patients as well as practicality in terms of obtaining adequate tissue samples for molecular studies.
url https://doi.org/10.1371/journal.pone.0221065
work_keys_str_mv AT kyoungminlee feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sojunglee feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT shinkyoyoon feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT baekyeolryoo feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sangwekim feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sanghyunchoi feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sangminlee feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT eunjinchae feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT yangsoonpark feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sejinjang feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT sooyeonpark feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT youngkwangyoon feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT seonghopark feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
AT taewonkim feasibilitysafetyandadequacyofresearchbiopsiesforcancerclinicaltrialsatanacademicmedicalcenter
_version_ 1714806066357731328